Other languages Initiator Pharma A/S

Equities

INIT

DK0060775872

Delayed Nasdaq Stockholm Other stock markets 03:51:48 2024-05-13 EDT			5-day change	1st Jan Change
9.12 ^SEK	-0.87%		-3.18%	-1.30%

05-10	Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-23	Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-22
Initiator Pharma Issues New Shares for Debt Conversion	02-21
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts	01-08
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine	23-10-06
Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction	23-09-19
Initiator Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25
Initiator Pharma A/S Obtains IP 2018 Patent in Europe for Treatment of Erectile Dysfunction and Depression	23-08-09
Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial	23-07-18
Initiator Pharma A/S (OM:INIT) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on May 26, 2023.	23-07-05
Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine	23-06-29
Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction	23-06-05
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05
Initiator Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02
Initiator Pharma A/S Completes Dosing in Phase 2a Trial with IP2018	23-03-06
Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations	22-12-20
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-04
Initiator Pharma A/S Provides an Update on Its Clinical Programs	22-11-04
Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study	22-09-21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Initiator Pharma A/S

Equities

INIT

DK0060775872

Other languages

Filters